Clinical Trials in Arizona

Showing 5881-5900 of 16,770 trials

Endpoint Determination Study Protocol

NCT03459482

This study is designed to evaluate the most applicable endpoints for evaluation of the Biomerica InFoods® IBS product.

Biomerica556 participantsStarted Jun 2018

Scottsdale, Arizona, United States • Jacksonville, Florida, United States • Wauconda, Illinois, United States +5 more locations

COMPLETEDPhase 1/231 miles

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

NCT01712217

The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer(NSCLC)

Astex Pharmaceuticals, Inc.220 participantsStarted Oct 2012

Scottsdale, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +62 more locations

Endpoint Determination Study Protocol

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Find Trials by Condition in Arizona

A Study of TAK-105 in Healthy Adults

EPIC: An Intervention for Early-stage AD Dyads - Adapted for Virtual Delivery

Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma

Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency

Evaluation of the Tympanostomy Tube Delivery System

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)